Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q3 2020 · 10-Q
Revenue$65.32M$65.32M+41.3% vs Q3 2019 Net Income$36.21M$36.21MN/M vs Q3 2019 EPS Diluted$0.25$0.25N/M vs Q3 2019 Gross Profit$3,480,000−49.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flowderived$6,084,000N/M Free Cash Flowderived$5,908,000N/M Margins · derivedGross margin5.3%−9.5 pt vs Q3 2019
Operating margin61.7%+114.8 pt vs Q3 2019
Net margin55.4%+109.5 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 2, 2020 · 33 d after period end